Immunotherapy May Highlight Neoadjuvant Treatment's Use in Lung Cancer

January 25, 2021

The radiographic and pathologic responses that have been seen with checkpoint inhibitors in lung cancer bodes well for the use of neoadjuvant therapy. However, the relationship between response and long-term outcomes, specifically with regard to overall survival, will have to be teased out before they become standard practice, explained David Spigel, MD.

Nivolumab Plus Cabozantinib Gets Priority Review for Advanced RCC Treatment

October 20, 2020

The FDA has granted a priority review designation to a supplemental biologics license application and supplemental new drug application for nivolumab (Opdivo) plus cabozantinib (Cabometyx) for the treatment of patients with advanced renal cell carcinoma.

Immunotherapy Combos in Advanced Nonsquamous NSCLC: What Does the Data Say?

September 29, 2020

The paradigm of advanced nonsquamous non–small cell lung cancer (NSCLC) is now one that necessitates discussions regarding the use of combination chemoimmunotherapy, combination immunotherapy, and single-agent immunotherapy, explained Jonathan Dowell, MD.

Investigational CAR T-Cell Product Plus Immunotherapy Is Active in DLBCL

September 26, 2020

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab (Keytruda) was found to have a tolerable safety profile and elicit durable complete responses (CRs) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to results of the single-arm, phase 1/2 ALEXANDER study that were presented during the virtual 2020 ESMO Congress.

Novel Molecule Enhances Immunotherapy Response in CRC, According to Early Data

September 19, 2020

The advent of immunotherapy has revolutionized multiple areas of cancer treatment, said Timothy Cragin Wang, MD, who added that the transformative potential of the modality has been mild at best in the field of colorectal cancer (CRC).